We summarize the current state of development for inhibitors against Menin‐KMT2A, DOT1L, KDM1A, and Polycomb complexes, and the arginine methyltransferase PRMT5 for the treatment of myeloid malignancies, lymphoma, and different solid tumors. The gene discussed is DOT1L; the disease is lymphoma.